| Mar 3 |
Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update
|
| Mar 3 |
Taysha Gene Therapies Inc to Host Earnings Call
|
| Mar 2 |
Earnings Scheduled For March 2, 2021
|
| Mar 1 |
Taysha Gene Therapies to Release Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 3
|
| Feb 26 |
Taysha Gene Therapies Announces Support of Rare Disease Day 2021
|
| Feb 16 |
Taysha Gene Therapies Announces Formation of Independent Scientific Advisory Board
|
| Feb 10 |
Taysha Gene Therapies Announces Participation in Upcoming Investor Healthcare Conferences
|
| Feb 9 |
Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS Disorders
|
| Feb 1 |
Taysha Gene Therapies Highlights Strategic Priorities and Provides 2021 Business Outlook
|
| Jan 26 |
Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer
|
| Jan 20 |
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
|
| Jan 19 |
Taysha Gene Therapies granted Orphan Drug designation for TSHA-105
|
| Jan 19 |
Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency
|
| Jan 15 |
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
|
| Jan 13 |
Taysha and UT Southwestern Medical Center launch innovation fund in gene therapy development push
|
| Jan 13 |
Taysha Gene Therapies and UT Southwestern Medical Center Launch Innovation Fund to Accelerate Advancement of AAV Gene Therapies for Monogenic Diseases of the Central Nervous System
|
| Jan 4 |
Taysha teams up with AllStripes to advance gene therapy for rare disorder
|
| Jan 4 |
Taysha Gene Therapies Announces Collaboration with AllStripes on SURF1-Associated Leigh Syndrome Clinical Development and Natural History
|
| Dec 29 |
Taysha Gene Therapies Expands Leadership Team to Deepen Manufacturing and Communications Capabilities
|
| Dec 24 |
What You Need To Know About Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Investor Composition
|
| Dec 21 |
Taysha on go with early-stage study with its gene therapy in inherited lysosomal storage disorder
|
| Dec 21 |
Taysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
|
| Dec 17 |
Taysha Gene Therapies Announces New cGMP Gene Therapy Manufacturing Facility
|
| Dec 17 |
Is TSHA A Good Stock To Buy Now?
|
| Dec 15 |
Taysha Gene Therapies Set to Join Russell 2000® Index on December 21, 2020
|
